240 related articles for article (PubMed ID: 24003397)
1. The value of somatostatin receptor imaging with In-111 Octreotide and/or Ga-68 DOTATATE in localizing Ectopic ACTH producing tumors.
Özkan ZG; Kuyumcu S; Balköse D; Ozkan B; Aksakal N; Yılmaz E; Sanlı Y; Türkmen C; Aral F; Adalet I
Mol Imaging Radionucl Ther; 2013 Aug; 22(2):49-55. PubMed ID: 24003397
[TBL] [Abstract][Full Text] [Related]
2. The role of 68Ga-DOTATATE PET in patients with neuroendocrine tumors and negative or equivocal findings on 111In-DTPA-octreotide scintigraphy.
Srirajaskanthan R; Kayani I; Quigley AM; Soh J; Caplin ME; Bomanji J
J Nucl Med; 2010 Jun; 51(6):875-82. PubMed ID: 20484441
[TBL] [Abstract][Full Text] [Related]
3. Usefulness of somatostatin receptor scintigraphy in patients with occult ectopic adrenocorticotropin syndrome.
Tabarin A; Valli N; Chanson P; Bachelot Y; Rohmer V; Bex-Bachellerie V; Catargi B; Roger P; Laurent F
J Clin Endocrinol Metab; 1999 Apr; 84(4):1193-202. PubMed ID: 10199752
[TBL] [Abstract][Full Text] [Related]
4. Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors.
Wild D; Bomanji JB; Benkert P; Maecke H; Ell PJ; Reubi JC; Caplin ME
J Nucl Med; 2013 Mar; 54(3):364-72. PubMed ID: 23297077
[TBL] [Abstract][Full Text] [Related]
5. Somatostatin receptor imaging in non-(131)I-avid metastatic differentiated thyroid carcinoma for determining the feasibility of peptide receptor radionuclide therapy with (177)Lu-DOTATATE: low fraction of patients suitable for peptide receptor radionuclide therapy and evidence of chromogranin A level-positive neuroendocrine differentiation.
Jois B; Asopa R; Basu S
Clin Nucl Med; 2014 Jun; 39(6):505-10. PubMed ID: 24662668
[TBL] [Abstract][Full Text] [Related]
6. Prospective evaluation of
Gabriel S; Garrigue P; Dahan L; Castinetti F; Sebag F; Baumstark K; Archange C; Jha A; Pacak K; Guillet B; Taïeb D
Clin Endocrinol (Oxf); 2018 Aug; 89(2):155-163. PubMed ID: 29788534
[TBL] [Abstract][Full Text] [Related]
7. 68Ga-DOTATATE PET/CT, 99mTc-HYNIC-octreotide SPECT/CT, and whole-body MR imaging in detection of neuroendocrine tumors: a prospective trial.
Etchebehere EC; de Oliveira Santos A; Gumz B; Vicente A; Hoff PG; Corradi G; Ichiki WA; de Almeida Filho JG; Cantoni S; Camargo EE; Costa FP
J Nucl Med; 2014 Oct; 55(10):1598-604. PubMed ID: 25168627
[TBL] [Abstract][Full Text] [Related]
8. Prospective Study of 68Ga-DOTATATE Positron Emission Tomography/Computed Tomography for Detecting Gastro-Entero-Pancreatic Neuroendocrine Tumors and Unknown Primary Sites.
Sadowski SM; Neychev V; Millo C; Shih J; Nilubol N; Herscovitch P; Pacak K; Marx SJ; Kebebew E
J Clin Oncol; 2016 Feb; 34(6):588-96. PubMed ID: 26712231
[TBL] [Abstract][Full Text] [Related]
9. Use of
Hou G; Jiang Y; Li F; Cheng X
Front Oncol; 2021; 11():762327. PubMed ID: 34692551
[TBL] [Abstract][Full Text] [Related]
10. Head-to-head comparison of
Liu Q; Zang J; Yang Y; Ling Q; Wu H; Wang P; Lu L; Zhu Z
Eur J Nucl Med Mol Imaging; 2021 Dec; 48(13):4386-4395. PubMed ID: 34146130
[TBL] [Abstract][Full Text] [Related]
11. Lack of utility of (111)In-pentetreotide scintigraphy in localizing ectopic ACTH producing tumors: follow-up of 18 patients.
Torpy DJ; Chen CC; Mullen N; Doppman JL; Carrasquillo JA; Chrousos GP; Nieman LK
J Clin Endocrinol Metab; 1999 Apr; 84(4):1186-92. PubMed ID: 10199751
[TBL] [Abstract][Full Text] [Related]
12. The Clinical Impact of [
Wannachalee T; Turcu AF; Bancos I; Habra MA; Avram AM; Chuang HH; Waguespack SG; Auchus RJ
Clin Endocrinol (Oxf); 2019 Aug; 91(2):288-294. PubMed ID: 31066920
[TBL] [Abstract][Full Text] [Related]
13. Differential uptake of (68)Ga-DOTATOC and (68)Ga-DOTATATE in PET/CT of gastroenteropancreatic neuroendocrine tumors.
Poeppel TD; Binse I; Petersenn S; Lahner H; Schott M; Antoch G; Brandau W; Bockisch A; Boy C
Recent Results Cancer Res; 2013; 194():353-71. PubMed ID: 22918768
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic utility of Gallium-68-somatostatin receptor PET/CT in ectopic ACTH-secreting tumors: a systematic literature review and single-center clinical experience.
Varlamov E; Hinojosa-Amaya JM; Stack M; Fleseriu M
Pituitary; 2019 Oct; 22(5):445-455. PubMed ID: 31236798
[TBL] [Abstract][Full Text] [Related]
15. Comparison of ⁶⁸Ga-DOTATATE and ⁶⁸Ga-DOTANOC PET/CT imaging in the same patient group with neuroendocrine tumours.
Kabasakal L; Demirci E; Ocak M; Decristoforo C; Araman A; Ozsoy Y; Uslu I; Kanmaz B
Eur J Nucl Med Mol Imaging; 2012 Aug; 39(8):1271-7. PubMed ID: 22526963
[TBL] [Abstract][Full Text] [Related]
16. Prevalence of hitherto unknown brain meningioma detected on
Parghane RV; Talole S; Basu S
World J Nucl Med; 2019; 18(2):160-170. PubMed ID: 31040748
[TBL] [Abstract][Full Text] [Related]
17. Long-Acting Somatostatin Analog Therapy Differentially Alters
Ayati N; Lee ST; Zakavi R; Pathmaraj K; Al-Qatawna L; Poon A; Scott AM
J Nucl Med; 2018 Feb; 59(2):223-227. PubMed ID: 28729431
[TBL] [Abstract][Full Text] [Related]
18. [
Pauwels E; Cleeren F; Tshibangu T; Koole M; Serdons K; Dekervel J; Van Cutsem E; Verslype C; Van Laere K; Bormans G; Deroose CM
Eur J Nucl Med Mol Imaging; 2020 Dec; 47(13):3033-3046. PubMed ID: 32617641
[TBL] [Abstract][Full Text] [Related]
19. Head-to-Head Comparison of
Zhu W; Cheng Y; Wang X; Yao S; Bai C; Zhao H; Jia R; Xu J; Huo L
J Nucl Med; 2020 Jun; 61(6):897-903. PubMed ID: 31676731
[No Abstract] [Full Text] [Related]
20. Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics.
Thapa P; Ranade R; Ostwal V; Shrikhande SV; Goel M; Basu S
Nucl Med Commun; 2016 Oct; 37(10):1030-7. PubMed ID: 27243215
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
